Showing results (861-870 of 895) with videos related to
Sort By:
Pageof 90
Drugs in R&D|January 20, 2017
A Review of Clinical Outcomes Associated with Two Meropenem Dosing StrategiesKyle John Wilby, Ziad Ghantous Nasr, Shereen Elazzazy, et al.Drugs in R&D|February 5, 2017
Risk Evaluation and Mitigation Strategies (REMSs): Are They Improving Drug Safety? A Critical Review of REMSs Requiring Elements to Assure Safe Use (ETASU)Pol F BoudesDrugs in R&D|April 8, 2017
Manufacturing of Recombinant Human Follicle-Stimulating Hormone Ovaleap® (XM17), Comparability with Gonal-f®, and Performance/ConsistencyRainer Winstel, Juergen Wieland, Beate Gertz, et al.Drugs in R&D|May 6, 2015
Single-Dose, Randomized, Open-Label, Two-Way, Crossover Bioequivalence Study of Two Formulations of Pregabalin 300 mg Hard Capsules in Healthy Volunteers Under Fasting ConditionsAugusto Filipe, Susana Almeida, Pedro Filipe Pedroso, et al.Drugs in R&D|April 9, 2020
Assessment of Vancomycin Pharmacokinetics and Dose Regimen Optimisation in Preterm NeonatesMwila Mulubwa, Heletje Aletta Griesel, Pierre Mugabo, et al.Drugs in R&D|April 23, 2021
Ammonia Removal by Metabolic Scavengers for the Prevention and Treatment of Hepatic Encephalopathy in CirrhosisRoger F ButterworthDrugs in R&D|February 22, 2023
Development of the Drug Product Formulation of the Bevacizumab Biosimilar PF-06439535 (Bevacizumab-bvzr)Rebecca L Ingram, Sarah E WeiserDrugs in R&D|September 7, 2012
Pharmacokinetics, safety, and tolerability of GLPG0259, a mitogen-activated protein kinase-activated protein kinase 5 (MAPKAPK5) inhibitor, given as single and multiple doses to healthy male subjectsFlorence Namour, Frédéric P Vanhoutte, Johan Beetens, et al.Drugs in R&D|July 23, 2020
Fingolimod as a Treatment in Neurologic Disorders Beyond Multiple SclerosisPablo Bascuñana, Luisa Möhle, Mirjam Brackhan, et al.Pageof 90